---

---

tags : Biocanada    source : Www.biospace.com   

save search

---

BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Published: 2024-04-15 (Crawled : 16:00) - biospace.com/
BETR | $0.4318 -4.13% -4.31% 680K |

n/a

| -3.46% | O: -1.21% H: 1.36% C: -4.41%
BETRF | $0.0721 -3.71% 15K |

Health Technology

| -3.65% | O: -8.49% H: 11.31% C: 11.31%
pharma conference

---

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
Published: 2024-03-19 (Crawled : 21:00) - biospace.com/
ABCL | $3.88 -0.77% -0.77% 980K |

| -15.69% | O: -1.96% H: 0.0% C: 0.0%
conference

---

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance
Published: 2024-02-21 (Crawled : 19:00) - biospace.com/
BHC | $8.69 1.05% 0.0% 2.9M |

Health Technology

| 1.05% | O: 0.0% H: 2.5% C: 0.81%
results

---

AbCellera Reports Full Year 2023 Business Results
Published: 2024-02-20 (Crawled : 23:00) - biospace.com/
ABCL | $3.88 -0.77% -0.77% 980K |

| -27.53% | O: 1.12% H: 0.93% C: -1.67%
business year results

---

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
Published: 2024-02-15 (Crawled : 13:30) - biospace.com/
RPTX 4 | $3.14 3.97% 3.82% 220K |

Health Technology

| -53.74% | O: 2.79% H: 4.14% C: -0.71%
rp-1664 first trial therapeutics

---

Repare Therapeutics to Regain Global Rights to Camonsertib
Published: 2024-02-12 (Crawled : 00:00) - biospace.com/
RPTX 4 | $3.14 3.97% 3.82% 220K |

Health Technology

| -59.25% | O: 0.0% H: 9.83% C: 8.8%
global therapeutics

---

Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
Published: 2024-02-07 (Crawled : 13:30) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M |

n/a

| 12.16% | O: 1.42% H: 0.0% C: -10.34%
japan grant program

---

Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22
Published: 2024-02-01 (Crawled : 20:00) - biospace.com/
BHC | $8.69 1.05% 0.0% 2.9M |

Health Technology

| 10.7% | O: 0.64% H: 2.15% C: 1.01%
health results

---

Zymeworks Announces Participation in Upcoming Investor Conferences - Jan 31, 2024
Published: 2024-01-31 (Crawled : 12:00) - biospace.com/
ZYME | $8.85 2.08% 2.03% 550K |

Health Technology

| -17.98% | O: -0.09% H: 3.57% C: 0.56%
BGNE | $129.51 -1.86% -1.89% 300K |

Health Technology

| -16.46% | O: -1.44% H: 0.26% C: -2.99%

---

CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
Published: 2024-01-30 (Crawled : 13:30) - biospace.com/
BHC | $8.69 1.05% 0.0% 2.9M |

Health Technology

| 4.32% | O: -0.36% H: 0.0% C: -1.33%
treatment gel acne

---

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
Published: 2024-01-25 (Crawled : 20:00) - biospace.com/
EPIX | $6.57 -2.23% -2.28% 100K |

Health Technology

| -28.1% | O: 0.46% H: 3.06% C: -22.99%
epi-7386 pharma symposium asco

---

Bloom Burton & Co. Announces the 2024 Bloom Burton Award
Published: 2024-01-25 (Crawled : 16:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -7.35% | O: -0.35% H: 0.0% C: 0.0%
award

---

Lexaria Releases Annual Letter from the CEO - January 24, 2024
Published: 2024-01-24 (Crawled : 14:00) - biospace.com/
LEXX | $2.27 0.89% 0.88% 62K |

Health Technology

| 44.74% | O: 3.29% H: 2.54% C: 0.0%
ceo

---

Satellos Receives Conditional Approval to Graduate to the Toronto Stock Exchange
Published: 2024-01-16 (Crawled : 12:30) - biospace.com/
MSCLF | $0.3901 18.14% 1K |

n/a

| Email alert Add to watchlist
approval

---

Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide
Published: 2024-01-04 (Crawled : 00:00) - biospace.com/
LEXX | $2.27 0.89% 0.88% 62K |

Health Technology

| 69.23% | O: -1.54% H: 9.38% C: 8.59%
drug technology

---

Bruker Announces Acquisition of Tornado Spectral Systems to Expand Its Biopharma Process Analytical Technology (PAT) Product Portfolio
Published: 2024-01-04 (Crawled : 20:00) - biospace.com/
BRKR | $77.725 -1.06% -1.07% 1.3M |

Health Technology

| 12.35% | O: -0.12% H: 2.53% C: 1.81%
biopharma acquisition technology

---

Fluzone High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza
Published: 2024-01-03 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -7.3% | O: 0.49% H: 0.0% C: -0.26%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -6.24% | O: 1.38% H: 0.0% C: 0.0%
vaccine influenza

---

Medicenna Extends Period to Exercise Certain Warrants - December 22, 2023
Published: 2023-12-22 (Crawled : 06:00) - biospace.com/
MDNAF | $1.24 -17.54% 67K |

n/a

| 290.16% | O: -1.41% H: 9.08% C: 1.96%

---

AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Published: 2023-12-20 (Crawled : 00:00) - biospace.com/
ABCL | $3.88 -0.77% -0.77% 980K |

| -31.87% | O: -1.94% H: 0.0% C: 0.0%
conference

---

Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA Treatment for Rare form of Emphysema
Published: 2023-12-20 (Crawled : 14:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M |

Health Technology

| -3.92% | O: 0.36% H: 0.14% C: -1.01%
rare services glassia contract treatment blood

---

Gainers vs Losers

67%

33%

Top 10 Gainers

---

Your saved searches

---